

**The listing of claims presented below replaces all prior versions and listing of claims in the application.**

**Listing of claims:**

1. (Currently amended)        Pharmaceutical agent, for the treatment or prophylaxis of cancer characterized in that it consists essentially of strontium, ~~at least one~~ or more amino acid selected from the group consisting of arginine, serine, asparagine, glycine, glutamine, lysine, and ~~at least one~~ or more mineral element selected from the group consisting of chromium, tin, vanadium and wolfram and one or more vitamins.
2. (Previously presented) Pharmaceutical agent according to claim 1, characterized in that strontium is present in the form of strontium ions.
3. (Previously presented) Pharmaceutical agent according to claim 1, characterized in that strontium is present in the form of strontium chloride or strontium oxide.
4. (Previously presented) Pharmaceutical agent according to claims 1 characterized in that it comprises 0.1–3 mg strontium, at least one L-amino acid selected from the group consisting of arginine, serine, asparagine, glycine, glutamine, lysine, in an amount of 2–5 g of each of the chosen amino acids, at least one mineral element selected from the group consisting of chromium, tin, vanadium and wolfram, in an amount of 1–3 mg of each of the chosen mineral elements, the amounts being calculated as daily intake.
5. (Previously presented) Pharmaceutical agent according to claim 1 characterized in that it comprises strontium, serine and vanadium.
6. (Previously presented) Pharmaceutical agent according to claim 1 characterized in that it comprises arginine and vanadium.

7. (Previously presented) Pharmaceutical agent according to claim 1 characterized in that it comprises strontium and isoleucin and at least one mineral element selected from the group consisting of chromium, tin, vanadium, selenium, and wolfram.

8. (Previously presented) Pharmaceutical agent according to claim 1 characterized in that it is in the form of a food additive or a food ingredient.

9 (currently amended) Pharmaceutical agent according to claim 8, characterized in that it is in the form of a dairy product, ~~preferably a yoghurt~~.

10. (Canceled)

11 (New) Pharmaceutical agent according to claim 8, characterized in that it is in the form of yoghurt.

12 (new) A method for the treatment or prophylaxis of cancer which comprises administering to a subject in need thereof a pharmaceutical agent which consists essentially of strontium, one or more amino acids selected from the group consisting of arginine, serine, asparagine, glycine, glutamine, lysine, one or more mineral elements selected from the group consisting of chromium, tin, vanadium and wolfram and one or more vitamins.

13. (New) A method of treatment or prophylaxis of cancer according to claim 12, characterized in that strontium is present in the pharmaceutical agent in the form of strontium ions.

14. (New) A method of treatment or prophylaxis of cancer according to claim 12,, characterized in that strontium is present in the pharmaceutical agent in the form of strontium chloride or strontium oxide.

15. (New) A method of treatment or prophylaxis of cancer according to claim 12, characterized in that the pharmaceutical agent comprises 0.1–3 mg strontium, at least one L-amino acid selected from the group consisting of arginine, serine, asparagine, glycine, glutamine, lysine, in an amount of 2–5 g of each of the chosen amino acids, at least one mineral element selected from the group consisting of chromium, tin, vanadium and wolfram, in an amount of 1–3 mg of each of the chosen mineral elements, the amounts being calculated as daily intake.

16 (New) A method of treatment or prophylaxis of cancer according to claim 12, characterized in that the pharmaceutical agent comprises strontium, serine and vanadium.

17 (New) A method of treatment or prophylaxis of cancer according to claim 12, characterized in that the pharmaceutical agent comprises arginine and vanadium.

18. (New) A method of treatment or prophylaxis of cancer according to claim 12, characterized in that the pharmaceutical agent comprises strontium and isoleucin and at least one mineral element selected from the group consisting of chromium, tin, vanadium, selenium, and wolfram.

19. (New) A method of treatment or prophylaxis of cancer according to claim 12, characterized in that the pharmaceutical agent is in the form of a food additive or a food ingredient.

20. (New) A method of treatment or prophylaxis of cancer according to claim 12, characterized in that the pharmaceutical agent is in the form of a dairy product.

21 (New) A method of treatment or prophylaxis of cancer according to claim 20 characterized in that the pharmaceutical agent is in the form of yoghurt.